AI-backed mRNA dog vaccine startup launches despite scientific skepticism

Paul Conyngham, an Australian tech entrepreneur, has announced Gamgee, a startup that aims to develop personalized mRNA cancer vaccines for animals, starting with dogs. The company has secured backing from Y Combinator and is now recruiting for clinical trials in Australia while building a global waitlist.

The Origin Story#

The venture emerged from Conyngham's highly publicized account of using large language models to help design a custom vaccine for his dog, Rosie, a Staffordshire bull terrier-Shar Pei mix. According to Conyngham's telling, he leveraged ChatGPT and computational genomics to create a targeted treatment, resulting in tumor shrinkage. The dog has since become the face of the startup, featured prominently across its website and marketing materials, including an AI-generated anime launch video.

The Broader Vision#

While the company initially focuses on canine cancer, its ambitions extend far beyond pets. Gamgee's stated roadmap includes developing personalized treatments for multiple disease types and eventually expanding to human applications. The startup promises to combine artificial intelligence with genetic analysis to tailor therapies across species.

Unresolved Questions#

Earlier reporting by The Verge raised significant concerns about how much credit the mRNA vaccine actually deserves. Researchers highlighted that Rosie received simultaneous treatments alongside the vaccine, making it impossible to isolate which intervention drove her improvement. Additionally, the precise role AI played in the design process remained unclear, with observers suggesting the narrative assigned outsized importance to automation while diminishing human expertise.

Moving Forward#

Despite these scientific caveats, Gamgee is moving quickly. The startup touts a roughly 75 percent tumor reduction in what it describes as its first documented case and claims the treatment can be delivered in approximately four weeks with minimal veterinary workflow disruption. The company is collaborating with Australian universities and is accepting global inquiries, though specific treatment costs remain undisclosed. For a company built on claims about a single case whose attribution remains murky, the goal of personalized human medicine represents notably ambitious scope.